Fragmentia-AI WGS paper: Independent test cohort by ichorCNA tumour fraction
AUC and sensitivity at the predefined cutoff, overall and within ichorCNA tumour-fraction strata, on the 5,996-sample independent test cohort.
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
1 recorded evaluation, 11 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.
Results
Results are available, but no reviewed comparison panel is linked in this release.
All evaluations
1 evaluation · 11 results. Different protocols are not a single leaderboard.
Protocol: Fragmentia-AI WGS paper: Independent test cohort by ichorCNA tumour fraction · Dataset: Fragmentia-AI WGS independent test cohort (5,996 samples, 0.05x ULP-WGS)
Sorted by AUROC (all cancers vs non-cancer) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.
| Tested configuration | AUROC (all cancers vs non-cancer) | AUROC (high-TF (> 5%) cancers vs non-cancer) | AUROC (low-TF (< 3%) cancers vs non-cancer) | AUROC (medium-TF (3-5%) cancers vs non-cancer) | Recall (sensitivity, all cancers, at the predefined cutoff (98% specificity in the training cohort)) | Recall (sensitivity, high-TF (> 5%) cancers, at the predefined cutoff (98% specificity in the training cohort)) | Recall (sensitivity, low-TF (< 3%) cancers, at the predefined cutoff (98% specificity in the training cohort)) | Recall (sensitivity, low-TF (< 3%) stage I/II cancers, at the predefined cutoff (98% specificity in the training cohort)) | Recall (sensitivity, low-TF (< 3%) stage III/IV cancers, at the predefined cutoff (98% specificity in the training cohort)) | Recall (sensitivity, medium-TF (3-5%) cancers, at the predefined cutoff (98% specificity in the training cohort)) | Specificity (non-cancer controls, at the predefined cutoff (98% specificity in the training cohort)) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fragmentia-AI WGS, high/medium/low-TF sequential fine-tuning (final model)Evaluation | 0.93 | 0.984 | 0.91 | 0.958 | 0.58 | 0.91 | 0.46 | 0.391 | 0.708 | 0.72 | 0.97 |
All 11 result rows with coverage, uncertainty and sources
Filter evaluations
Applied filters: All linked evaluations
Source checking is not independent reproduction. Release 2026-11-21-c8bea25e5abb.
Methods and evaluation design
Procedure, tasks and evaluated configurations
Recorded evaluations
Each evaluation records what was tested and under which conditions.
Baseline coverage
Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.
0 of 2 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.
No execution recipe linked to this protocol. Recipe availability does not establish a completed evaluation.
- Author-reported evaluations
- 1
Literature evidence is not a Rewire measurement. Executed but unpublished runs and private review status are not included.
Null control
Proposed control: requires review
Select a task-valid null control after reviewing inputs and metric
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Conventional reference
Proposed control: requires review
Select an upstream conventional reference after reviewing the full protocol
Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.
This is a suggested selection rule, not a validated method or a measured score.
Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)
Coverage is derived from release 2026-11-21-c8bea25e5abb. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.
Run instructions
No runnable recipe has been reviewed for this protocol. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
0 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|
No evidence rows match these filters. Choose another scope or clear the search.
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
2 source records and release history
- Generalizable cancer detection from ultra-low-pass WGS via deep contextual modeling of cfDNA sequences · Original source · Molecular Biomedicine, published online 2026-08-12; Europe PMC full-text JATS XML of PMC13469060
- Fragmentia-AI WGS paper, Supplementary Material 1 (Tables S1-S4, Figures S1-S9) · Original source · 43556_2026_538_MOESM1_ESM.docx, publisher supplementary file
Technical metadata and record identifiers
Technical metadata for this record is tracked under stable ID ctdnalit-20261011-fragmentiawgs2026-protocol-test.
Source locator: Results P19; Table S4